## Supplementary Tables

**Supplementary table 1**: Individual patient tumor type specifications and number of injected myDC for individual patients after thawing and washing.

| PATIENT | TUMOR TYPE | | NUMBER OF INJECTED MYDC CD1C + CD141 (X $10^6$) |
|---|---|---|---|
| **1A** | NSCLC | Stage IV | 14,1 |
| **2A** | NSCLC | Stage IV | 15,3 |
| **3B** | NSCLC | Stage IV | 37,6 |
| **4A** | NSCLC | Stage IV | NA |
| **5A** | NSCLC | Stage IV | 13,6 |
| **6A** | NSCLC | Stage IV | NA |
| **7B** | NSCLC | Stage IV | 6,5 |
| **8A** | Uveal melanoma | Stage IV-M1c | 13,2 |
| **9B** | Cutaneous melanoma | Stage IV-M1a | NA |
| **10A** | Cutaneous melanoma | Stage IV-M1a | 23,9 |
| **11A** | Cutaneous melanoma | Stage IV-M1b | 17,2 |
| **13A** | NSCLC | Stage IV | 15,6 |
| **14A** | Cutaneous melanoma | Stage IV-M1a | 23,3 |
| | | | **Average:** 18.0<br>**Median:** 15,4626 |

**Supplementary table 2**: All adverse events

| ADVERSE EVENTS n, (%) | | | | |
|---|---|---|---|---|
| *CTCAE v 5.0 grade* | **Grade 1 or 2** | | **Grade 3** | |
| | **Arm B** | **Arm A** | **Arm B** | **Arm A** |
| Abdominal pain | | 1 (10) | | |
| Adrenal insufficiency | | | | 1 (10) |
| Amenorrhea | | 1 (10) | | |
| Anemia | | 1 (10) | | |
| Anorexia | 1 (33,3) | | | |
| Arthritis | 1 (33,3) | | | |
| Chills | 1 (33,3) | | | |
| Conjuctivitis | | 1 (10) | | |
| Constipation | 1 (33,3) | | | |
| Cough | 2 (66,6) | | | |
| COVID | | 1 (10) | | |
| Diarrhea | | 1 (10) | | |
| Dyspnea | 1 (33,3) | 2 (20) | | |
| Eczema | | 1 (10) | | |
| Fatigue | 2 (66,6) | 4 (40) | | |
| Fever | | 1 (10) | | |
| Flu-like symptoms | 1 (33,3) | | | |
| GERD | | 1 (10) | | |
| Horner syndrome | 1 (33,3) | | | |
| Hypertension | | | | 1 (10) |

| | | | | |
|---|---|---|---|---|
| Hyperthyroidism | | 1 (10) | | |
| hypocalcemia | | 1 (10) | | |
| Hypophysitis | | | | 1 (10) |
| Hypothyroïdism | 1 (33,3) | | | |
| Infection | | 1 (10) | | |
| Injection site reaction | | 3 (30) | | |
| Ischemia cerebrovascular | | | | 1 (10) |
| Lymphopenia | | 1 (10) | | |
| Malaise | | 1 (10) | | |
| Muscle weakness lower limb | | 1 (10) | | |
| Nausea | 1 (33,3) | 4 (40) | | |
| Paresthesia | | 1 (10) | | |
| Peripheral sensory neuropathy | | 1 (10) | | |
| Pleuritic pain | | 1 (10) | | |
| Pneumonitis | 1 (33,3) | 2 (20) | | 1 (10) |
| Pneumothorax | | | 1 (33,3) | |
| Pruritus | 1 (33,3) | | | |
| Nycturie | | 1 (10) | | |
| Skin infection | | 1 (10) | | |
| Tumor Pain | 1 (33,3) | 1 (10) | | |
| Vomiting | | 1 (10) | | |
| Weight loss | | 2 (20) | | |

***There were no grade 4 or 5 adverse events***